SI press release
RTPR•05/11/2026•16:11 ET
0
Key Highlights
- ➤Q3 net revenue $16.2 million, up 38% year over year
- ➤Full-year 2026 revenue guidance raised to $68 million-$70 million
- ➤Q3 gross margin reached 78.5%, versus 76.2% last year
- ➤Q3 implant systems sold rose approximately 34% to 2,126
- ➤InSet Go completed first surgical cases; InSet Neo FDA submission planned
Expert Statements
Rob Ball, CEO of Shoulder Innovations
“Our third quarter results reflect the consistency of our commercial model, as we added new surgeons ahead of plan, grew volume within our existing customer base, and kept our product roadmap moving.”
Rob Ball, CEO of Shoulder Innovations
“This performance enabled us to again raise our outlook for the full year, and confirmed our conviction regarding our ability to grow market share through a differentiated approach to shoulder surgical care.”
Rob Ball, CEO of Shoulder Innovations
“From a new product standpoint, we're pleased to have recently completed the first successful cases with InSet Go, our next-generation glenoid implant.”
Rob Ball, CEO of Shoulder Innovations
“Beyond our own pipeline, our partners are extending what our platform can offer, with a new partnership bringing bespoke solutions for the most complex revision cases and our soft tissue relationship positioning us to serve more of each shoulder specialist's practice.”
Rob Ball, CEO of Shoulder Innovations
“As we head into the final quarter of 2026, the commercial organization we've built continues to perform, our pipeline has never been deeper, and we look forward to finishing the year strong and building on that momentum into 2027, including the planned FDA submission of InSet Neo, our shoulder-specific robotic platform.”
Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook PR Newswire
GRAND RAPIDS, Mich., Nov. 5, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.